drugset
drugset / Trial / NCT07276581

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581 ↗

Phase 2 Recruiting 320 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Timeline

Start
2025-12-15
Primary completion
2027-11-12
Completion
2028-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1163 Unknown — Subcutaneous

Indications

rheumatoid arthritis